APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
HR 8529, the Protecting Access to Affordable Medicines Act, provisions relating to Medicaid rebate penalties on generic drugs
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Pharmacy PHA
HR 938, the Bringing Low-cost Options and Competition while Keeping Incentives for new Generics (BLOCKING) Act of 2019, provisions relating to the Hatch-Waxman Acts 180-day exclusivity framework
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.